Oxford-AstraZeneca vaccine effective against B.1.1.7 SARS-CoV-2 variant

The coronavirus disease (COVID-19) pandemic continues to spread globally, with new variants emerging. One of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants is the B.1.1.7 or U.K. variant. It is still unclear if the developed vaccines can protect against new emerging variants.

Now, researchers at the COVID-19 Genomics United Kingdom Consortium, the AMPHEUS Project, and the Oxford COVID-19 Vaccine Trial Group released the results of their exploratory analysis of a randomized controlled trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine against the SARS-CoV-2 variant of concern 202012/01 or the B.1.1.7 variant.

Published in The Lancet, the study explores if the Oxford-AstraZeneca vaccine works well in protecting against the B.1.1.7 variant, otherwise known as the U.K. variant.
for more:https://exe.io/JQ9vl